# US 2012/0252880 A1 · Oligonucleotide Complex Compositions And Methods Of Use As Gene Alteration Tools

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252880 A1
- Document ID: US20120252880A1
- Status: Published application
- Kind: A1
- Application number: 13/418,998
- Filed: 2012-03-13
- Published: 2012-10-04
- Earliest claimed: 2004-03-29
- Assignees: The General Hospital Corporation
- Inventors: David R. Tabatadze; Paul C. Zamecnik; Malay K. Raychowdhury; Horacio F. Cantiello
- Web page: https://patentgrep.com/patent/US20120252880A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/1024: {In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/07: containing a mitochondrial localisation signal
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2320/30: Special therapeutic applications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compositions and methods of treatments of cells are provided for altering the phenotype of a cell by administering an oligonucleotide complex to the cell, the complex having two strands and chemical modifications.

## Claims

### Claim 1

A method for targeted gene repair, comprising
contacting a non-repaired target RNA with a phosphorothioate (PS) containing sequence comprising a deoxynucleotide with RNase H resistant flanking ends;
contacting the non-repaired target RNA with an RNA oligonucleotide complex comprising a first oligonucleotide and a second oligonucleotide,
said first oligonucleotide comprising a sequence complementary to a repaired target RNA, wherein the RNA sequence of the first oligonucleotide comprises an RNase H-resistant modification, and wherein the RNase H-resistant modification is the addition of a 2-O-methyl moiety, and
said second oligonucleotide comprises an RNA sequence complementary to at least 6 nucleotides of the first oligonucleotide at the site in the sequence of the first oligonucleotide which is not complementary to the non-repaired target RNA; and
hybridizing said complex to said non-repaired target RNA in the presence of an RNase, wherein a repaired RNA is produced.

### Claim 2 (depends on 1)

The method of claim 1, wherein the repaired target RNA comprises a wild-type sequence.

### Claim 3 (depends on 2)

The method of claim 2, wherein the non-repaired target RNA comprises a mutation compared to said wild type sequence.

### Claim 4 (depends on 3)

The method of claim 3, wherein said mutation is a substitution, deletion or insertion of at least one base pair compared to said wild type sequence.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein said first oligonucleotide is at least 10 nucleotides in length.

### Claim 8 (depends on 7)

The method of claim 7, wherein said first oligonucleotide comprises about 33 nucleotides.

### Claim 9 (depends on 1)

The method of claim 1, wherein said second oligonucleotide comprises at least 7 nucleotides.

### Claim 10 (depends on 9)

The method of claim 9, wherein said second oligonucleotide comprises about 11 nucleotides.

### Claim 11 (depends on 1)

The method of claim 1, wherein said first oligonucleotide and said second oligonucleotide are annealed.

### Claim 12 (depends on 1)

The method of claim 1, wherein contacting said target RNA occurs within a cell.

### Claim 13 (depends on 12)

The method of claim 12, wherein said cell is in vitro, ex vivo or in vivo.

### Claim 14 (depends on 12)

The method of claim 12, wherein said cell is a human cell.

### Claim 15

A method for treating or ameliorating a symptom of cystic fibrosis in a subject in need thereof, comprising
administering a phosphorothioate (PS) containing sequence comprising a deoxynucleotide with RNase H resistant flanking ends,
administering an RNA oligonucleotide complex directed to a non-repaired target RNA, said complex comprising a first oligonucleotide and a second oligonucleotide,
said first oligonucleotide comprising a sequence complementary to a repaired target RNA, wherein the RNA sequence of the first oligonucleotide comprises an RNase H-resistant modification, and wherein the RNase H-resistant modification is the addition of a 2-O-methyl moiety, and
said second oligonucleotide comprises an RNA sequence complementary to at least 6 nucleotides of the first oligonucleotide at the site on the sequence of the first oligonucleotide which is not complementary to the non-repaired target RNA; and
wherein administration produces a repaired targeted RNA, thereby treating or ameliorating symptom of cystic fibrosis.

### Claim 16 (depends on 15)

The method of claim 15, wherein the repaired target RNA comprises a wild-type sequence.

### Claim 17 (depends on 16)

The method of claim 16, wherein the non-repaired target RNA comprises a mutation compared to said wild type sequence.

### Claim 18 (depends on 17)

The method of claim 17, wherein said mutation is a substitution, deletion or insertion of at least one base pair compared to said wild type sequence.

### Claim at position 18

19-20. (canceled)

### Claim 21 (depends on 15)

The method of claim 15, wherein said first oligonucleotide is at least 10 nucleotides in length.

### Claim 22 (depends on 21)

The method of claim 21, wherein said first oligonucleotide comprises about 33 nucleotides.

### Claim 23 (depends on 15)

The method of claim 15, wherein said second oligonucleotide comprises at least 7 nucleotides.

### Claim 24 (depends on 23)

The method of claim 23, wherein said second oligonucleotide comprises about 11 nucleotides.

### Claim 25 (depends on 15)

The method of claim 15, wherein said first oligonucleotide and said second oligonucleotide are annealed.

### Claim 26

An RNA oligonucleotide complex for modulating the expression or activity of a cystic fibrosis transmembrane conductance regulator (CFTR) gene product, the complex comprising a first oligonucleotide and a second oligonucleotide, said said first oligonucleotide comprising a sequence complementary to a repaired target RNA, wherein the RNA sequence of the first oligonucleotide comprises an RNase H-resistant modification, and wherein the RNase H-resistant modification is the addition of a 2-O-methyl moiety, and said second oligonucleotide comprises an RNA sequence complementary to at least 6 nucleotides of the first oligonucleotide at the site in the sequence of the first oligonucleotide which is not complementary to the non-repaired target RNA, wherein said first and second oligonucleotide are annealed.

### Claim at position 25

27-40. (canceled)
